Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05063539 · ClinicalTrials.gov registry record · Phase 2

A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease

A Phase 2 study of Alzheimer Disease, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 2
Development phase
327
Enrollment target
20
Study locations

NCT05063539 is a Phase 2 study of Alzheimer Disease that has completed, run by Eli Lilly and Company. The registered enrollment target is 327 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05063539, a Phase 2 study of Alzheimer Disease, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 2
Development phase
327 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to assess the safety, tolerability and effect of study drug LY3372689 in participants with early symptomatic Alzheimer's Disease

Conditions Studied

Alzheimer Disease

Interventions

  • DRUG Placebo
  • DRUG LY3372689

Study Locations (20)

Florida

  • JEM Research Institute - Atlantis
  • VIN-Julie Schwartzbard - Aventura
  • Neurology Offices of South Florida - Boca Raton
  • Brain Matters Research - Delray Beach
  • Neuropsychiatric Research Center of Southwest Florida - Fort Myers
  • K2 Medical Research - Maitland
  • ClinCloud - Viera - Melbourne
  • Merritt Island Medical Research, LLC - Merritt Island
  • VIN-Andrew Lerman - Miami
  • IMIC, Inc. - Miami
  • VIN-Victor Faradji - Miami
  • Suncoast Clinical Research, Inc. - New Port Richey
  • Renstar Medical Research - Ocala
  • VIN- Margarita Almeida El-Ramey - Pembroke Pines
  • Brain Matters Research - Stuart

California

  • Hope Clinical Research, Inc. - Canoga Park
  • Neuro-Pain Medical Center - Fresno
  • Irvine Clinical Research - Irvine
  • Sharp Mesa Vista Hospital - San Diego

Connecticut

  • Institute for Neurodegenerative Disorders - New Haven

Trial Details

FieldValue
Enrollment Target 327 participants
Start Date 2021-09-16
Est. Completion 2025-05-22
Phase Phase 2

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05063539

The ClinicalTrials.gov registry entry for NCT05063539 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 327 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (88% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05063539 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Florida, California, Connecticut.

Frequently Asked Questions

What is clinical trial NCT05063539 about?

NCT05063539 is a clinical study titled "A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease". The purpose of this study is to assess the safety, tolerability and effect of study drug LY3372689 in participants with early symptomatic Alzheimer's Disease

What is the current status of trial NCT05063539?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 327 participants. The study started on 2021-09-16. Estimated completion is 2025-05-22.

What conditions does trial NCT05063539 study?

This clinical trial studies the following conditions: Alzheimer Disease.

What interventions are being tested in trial NCT05063539?

The interventions under investigation include: Placebo (DRUG), LY3372689 (DRUG).

Who is sponsoring clinical trial NCT05063539?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05063539 being conducted?

This trial has 20 study locations across California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alzheimer Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Alzheimer Disease

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.